American Association of Pharmaceutical Scientists National Biotechnology Conference short course: Translational challenges in developing antibody-drug conjugates

mAbs

Volumn 5, Issue 1, 2013, Pages 5-12

  Thudium, Karen ^a   Bilic, Sanela ^a   Leipold, Douglas ^b   Mallet, William ^c   Kaur, Surinder ^b   Meibohm, Bernd ^d   Erickson, Hans ^e   Tibbitts, Jay ^b,h   Zhao, Hong ^f   Gupta, Manish ^g  

^a NOVARTIS PHARMA AG   (Switzerland)

^b GENENTECH INC   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^e IMMUNOGEN INC   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h UCB PHARMA   (Belgium)

Author keywords

ADC; Brentuximab vedotin; Linker; Pharmacokinetics; Trastuzumab emtansine

Indexed keywords

AVE 9633; BAY 79 4620; BAY 94 09343; BRENTUXIMAB VEDOTIN; BT 062; CANTUZUMAB RAVTANSINE; GLEMBATUMUMAB VEDOTIN; IMGN 368; IMGN 388; INOTUZUMAB OZOGAMICIN; LORVOTUZUMAB MERTANSINE; MDX 1203; MONOCLONAL ANTIBODY; SAR 3419; SAR 566658; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VORSETUZUMAB MAFODOTIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LYMPHOMA; BREAST CANCER; CELL CYCLE ARREST; CONFERENCE PAPER; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; DRUG SAFETY; ENDOSOME; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; KIDNEY CARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOTECHNOLOGY; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84872861443     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22909     Document Type: Conference Paper

References (11)

1. Deng R, Iyer S, Theil F P, Mortensen DL, Fielder P.J., Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 2011; 3:61-6; PMID:20962582; http://dx.doi.org/10.4161/mabs.3.1.13799
2. Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts J, Girish S.R., Gupta M., et al Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther 2012; 92:520-7; PMID:22968044; http://dx.doi.org/10.1038/clpt.2012.153
3. Thon JN, Devine M T, Jurak Begonja A, Tibbitts J, Italiano JE Jr. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 2012; 120:1975-84; PMID:22665936; http://dx.doi.org/10.1182/blood-2012-04-420968
4. rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29:398-405; PMID:21172893; http://dx.doi.org/10.1200/JCO.2010.29.5865
5. Krop IE, Beeram M, Modi S., Jones SF, Holden SN, Yu W, et al Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28:2698-704; PMID:20421541; http://dx.doi.org/10.1200/JCO.2009.26.2071
6. Mahapatra KDW, Bumbaca D, Shen B. 2011. T-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner. AACR-NCI-EORTC, ed., San Francisco, California: AACR
7. Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 2012; 29:2354-66; PMID:22740180; http://dx.doi.org/10. 1007/s11095-012-0800-y
8. Bender BC, Schaedeli-Stark F, Koch R., Joshi A, Chu Y W, Rugo H, et al A population pharmacokinetic/ pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 2012; 70:591-601; PMID:22886072; http://dx.doi.org/10.1007/s00280-012- 1934-7
9. Shen BQ, Bumbaca D, Saad O., Yue Q, Pastuskovas CV, Khojasteh S.C., et al Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 2012; 13:901-10; PMID:22475269; http://dx.doi.org/10.2174/138920012802138598
10. Girish S, Gupta M, Wang B., Lu D, Krop IE, Vogel C.L., et al Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012; 69:1229-40; PMID:22271209; http://dx.doi.org/10.1007/s00280-011- 1817-3
11. rd, Wang B, Dees EC, Cortes J, Joshi A, et al. Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Curr Drug Metab 2012; 13:911-22; PMID:22475266; http://dx.doi.org/10.2174/ 138920012802138688